Gynecologic Oncology Group

妇科肿瘤组

• 批准号: 7683571
• 负责人: Philip J. DiSaia
• 金额: $ 7.64万
• 依托单位: GYNECOLOGIC ONCOLOGY GROUP
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-05-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7683571
• 关键词: Address; Area; Basic Science; Biology; Carboplatin; Categories; Cervical; Cervix carcinoma; Clinical; Clinical Research; Clinical Trials; Collection; Combination Chemotherapy; Commit; Communities; Development; Developmental Therapeutics Program; Diagnostic; Discipline; Disease; Early Diagnosis; Early treatment; Education; Endometrial; Endometrial Carcinoma; Evaluation; Fostering; Future; Gynecologic; Gynecologic Oncology Group; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Medical Informatics; Modality; Nonprofit Organizations; Outcome; Ovarian Carcinoma; Paclitaxel; Patient Care; Patients; Phase; Phase II Clinical Trials; Platinum; Prevention program; Procedures; Process; Progress Reports; Public Health; Purpose; Quality of Care; Quality of life; Quality-of-Life Assessment; Radiosurgery; Randomized Controlled Clinical Trials; Rare Diseases; Recurrence; Reporting; Research; Research Personnel; Risk; Series; Staging; Standards of Weights and Measures; System; Systemic Therapy; Techniques; Testing; Therapeutic; Translational Research; anticancer research; base; cancer prevention; chemotherapeutic agent; chemotherapy; cytotoxic; data management; design; improved; innovation; interdisciplinary collaboration; multidisciplinary; organizational structure; processing speed; programs

DESCRIPTION (provided by applicant): The Gynecologic Oncology Group is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic research in the field of Gynecologic Malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care. The Gynecologic Oncology Group (GOG) is the foremost multidisciplinary cooperative clinical trial research group devoted to the study of gynecologic malignancies. Since its inception in 1979, the GOG has been a recognized leader in the development of new forms of treatment and has relied on the Phase II trials as the design to identify new information. Supporting that major activity are the concerted efforts of: multidisciplinary committees; committees focused on special areas of expertise such as developmental therapeutics, quality of life, translational research, and cancer prevention and control; and modality committees providing recent approaches and procedures in each of the relevant diagnostic and therapeutic disciplines. The GOG has an active, effective program in the study of new chemotherapeutic agents and innovative therapeutic approaches in gynecologic cancers; and this program has introduced important findings for study in the phase III setting. In patients with advanced cervical, endometrial and ovarian cancers, the GOG has defined significant improvement associated with the use of systemic therapy. The GOG has performed a series of trials which have defined: the standard use of paclitaxel plus carboplatin in ovarian carcinoma, concurrent platinum-based chemoradiation in stage IB-IVA carcinoma of the cervix, combination chemotherapy in advanced or recurrent carcinoma of the cervix, and chemotherapy in patients with advanced or high-risk limited endometrial carcinoma. In addition, the GOG has been active in developing new mechanisms to enhance translational research, cancer prevention and control and medical informatics. The Group has collaborated actively with the NCI in evaluating new data management collection and reporting systems. Future efforts will focus on: evolving a better understanding of the biology of gynecologic cancers, improving patient outcome through continued trials of both cytotoxic and biologically targeted agents in combination with surgery and radiation, and enhancing quality of life of patients with gynecologic cancers.

描述（由申请人提供）：妇科肿瘤小组是一个非营利组织，其目的是促进妇科恶性肿瘤领域临床和基础研究的卓越质量和完整性。集团致力于在临床试验开发、执行、分析和结果分发方面保持最高标准。对我们流程的持续评估是为了不断提高患者护理质量。 妇科肿瘤学组（GOG）是最重要的多学科合作临床试验研究组，致力于妇科恶性肿瘤的研究。自 1979 年成立以来，GOG 一直是新型治疗开发领域公认的领导者，并依靠 II 期试验作为识别新信息的设计。支持这项主要活动的是以下各方的共同努力： 多学科委员会；委员会专注于特殊的专业领域，例如发育治疗、生活质量、转化研究以及癌症预防和控制；和模式委员会提供每个相关诊断和治疗学科的最新方法和程序。 GOG 在研究妇科癌症的新化疗药物和创新治疗方法方面拥有积极、有效的计划；该计划引入了第三阶段研究的重要发现。对于晚期宫颈癌、子宫内膜癌和卵巢癌患者，GOG 定义了与使用全身治疗相关的显着改善。 GOG 进行了一系列试验，确定了：紫杉醇加卡铂在卵巢癌中的标准使用、IB-IVA 期宫颈癌的同步铂类放化疗、晚期或复发性宫颈癌的联合化疗，以及晚期或高危局限性子宫内膜癌患者的化疗。此外，GOG还积极开发新机制，以加强转化研究、癌症预防和控制以及医学信息学。该集团与 NCI 积极合作，评估新的数据管理收集和报告系统。未来的努力将集中于：更好地了解妇科癌症的生物学，通过细胞毒性和生物靶向药物结合手术和放射的持续试验来改善患者的预后，以及提高妇​​科癌症患者的生活质量。